Key terms
About CERE
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CERE news
Yesterday
2:45am ET
Hold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisition
Apr 18
6:37am ET
Cerevel Therapeutics’ tavapadon meets Phase 3 primary endpoint in Parkinson’s
Mar 06
11:56pm ET
Cerevel Therapeutics: Hold Rating Amidst Pending AbbVie Acquisition
Feb 28
5:33am ET
Maintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational Costs
Feb 16
5:04pm ET
Cerevel Therapeutics Advances in Merger Amid FTC Review
Feb 15
6:46am ET
Cerevel Therapeutics price target raised to $45 from $25 at Mizuho
Feb 08
7:33am ET
Neurocrine price target raised to $106 from $100 at Piper Sandler
Jan 22
7:08am ET
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
No recent press releases are available for CERE
CERE Financials
Key terms
Ad Feedback
CERE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CERE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
